{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:31:07Z","timestamp":1787319067338,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Acromegaly is a rare disease that can be challenging to treat due to residual pituitary adenoma after surgery or variable response to medical treatments. The primary aim of the study was to evaluate the path of treatment and long-term outcome of acromegaly after pituitary surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with acromegaly who had undergone surgery for a growth hormone-producing pituitary neuroendocrine tumor also known as a pituitary adenoma, at Sahlgrenska University Hospital between 1994 and 2019 were included in the study. Medical records from diagnosis to the end of study (November 2022) were reviewed for surgical outcome and treatment patterns related to acromegaly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the cohort of 103 patients, 111 surgeries were performed. Mean follow-up duration was 12.7 (range: 0\u201337) years. Lesions were identified as a macroadenoma in 76 (76.8%) cases. At post-surgical follow-up until discharge from hospital, surgical complications and new pituitary hormone deficiency or syndrome of inappropriate antidiuretic hormone secretion occurred in 37% of cases. At 1-year post-surgery follow-up, 50% of evaluable patients achieved biochemical control of acromegaly. Of the 96 patients who had follow-up &gt;\u20091 year, 53 (51.5%) had no additional medication for acromegaly after surgery until end of their follow-up. From diagnosis to the end of follow-up, 53 patients received medical therapy and seven were treated with radiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>About half of the patients had biochemical control of acromegaly 1-year post-surgery. Treatment patterns reflected the complexity of post-surgical management and provided an overview of the long-term clinical progression in patients with acromegaly following pituitary surgery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-025-01503-6","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T15:15:00Z","timestamp":1740237300000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-term clinical outcome of 103 patients with acromegaly after pituitary surgery"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9700-2381","authenticated-orcid":false,"given":"Anna","family":"Pennlund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Olsson","family":"Bontell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Skoglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Hall\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Car\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudmundur","family":"Johannsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"issue":"2","key":"1503_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1530\/EJE-21-0216","volume":"185","author":"S Crisafulli","year":"2021","unstructured":"Crisafulli S, Luxi N, Sultana J et al (2021) Global epidemiology of acromegaly: a systematic review and meta-analysis. Eur J Endocrinol 185(2):251\u2013263. https:\/\/doi.org\/10.1530\/EJE-21-0216","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1503_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11102-016-0754-x","volume":"20","author":"A Lavrentaki","year":"2017","unstructured":"Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N (2017) Epidemiology of acromegaly: review of population studies. Pituitary 20(1):4\u20139. https:\/\/doi.org\/10.1007\/s11102-016-0754-x","journal-title":"Pituitary"},{"issue":"6","key":"1503_CR3","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1007\/s00464-014-3815-0","volume":"29","author":"F Wang","year":"2015","unstructured":"Wang F, Zhou T, Wei S et al (2015) Endoscopic endonasal transsphenoidal surgery of 1,166 pituitary adenomas. Surg Endosc 29(6):1270\u20131280. https:\/\/doi.org\/10.1007\/s00464-014-3815-0","journal-title":"Surg Endosc"},{"issue":"4","key":"1503_CR4","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.3171\/2010.7.FOCUS10153","volume":"29","author":"PG Campbell","year":"2010","unstructured":"Campbell PG, Kenning E, Andrews DW, Yadla S, Rosen M, Evans JJ (2010) Outcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas. Neurosurg Focus 29(4):E5. https:\/\/doi.org\/10.3171\/2010.7.FOCUS10153","journal-title":"Neurosurg Focus"},{"issue":"1","key":"1503_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s11102-016-0765-7","volume":"20","author":"M Buchfelder","year":"2017","unstructured":"Buchfelder M, Schlaffer SM (2017) The surgical treatment of acromegaly. Pituitary 20(1):76\u201383. https:\/\/doi.org\/10.1007\/s11102-016-0765-7","journal-title":"Pituitary"},{"issue":"1","key":"1503_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1210\/jcem.85.1.6318","volume":"85","author":"A Colao","year":"2000","unstructured":"Colao A, Baldelli R, Marzullo P et al (2000) Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 85(1):193\u2013199. https:\/\/doi.org\/10.1210\/jcem.85.1.6318","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1503_CR7","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1210\/clinem\/dgac400","volume":"107","author":"D Esposito","year":"2022","unstructured":"Esposito D, Olsson DS, Franz\u00e9n S et al (2022) Effect of diabetes on morbidity and mortality in patients with acromegaly. J Clin Endocrinol Metab 107(9):2483\u20132492. https:\/\/doi.org\/10.1210\/clinem\/dgac400","journal-title":"J Clin Endocrinol Metab"},{"issue":"15","key":"1503_CR8","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1093\/eurheartj\/ehab822","volume":"43","author":"S Hong","year":"2022","unstructured":"Hong S, Kim KS, Han K, Park CY (2022) Acromegaly and cardiovascular outcomes: a cohort study. Eur Heart J 43(15):1491\u20131499. https:\/\/doi.org\/10.1093\/eurheartj\/ehab822","journal-title":"Eur Heart J"},{"issue":"5","key":"1503_CR9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1530\/EJE-18-0015","volume":"178","author":"D Esposito","year":"2018","unstructured":"Esposito D, Ragnarsson O, Granfeldt D, Marlow T, Johannsson G, Olsson DS (2018) Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study. Eur J Endocrinol 178(5):459\u2013469. https:\/\/doi.org\/10.1530\/EJE-18-0015","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1503_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1530\/EJE-16-0623","volume":"176","author":"E Les\u00e9n","year":"2017","unstructured":"Les\u00e9n E, Granfeldt D, Houchard A et al (2017) Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study. Eur J Endocrinol 176(2):203\u2013212. https:\/\/doi.org\/10.1530\/EJE-16-0623","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1503_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10014-017-0307-7","volume":"35","author":"H Nishioka","year":"2018","unstructured":"Nishioka H, Inoshita N (2018) New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors. Brain Tumor Pathol 35(2):57\u201361. https:\/\/doi.org\/10.1007\/s10014-017-0307-7","journal-title":"Brain Tumor Pathol"},{"issue":"1","key":"1503_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","volume":"33","author":"SL Asa","year":"2022","unstructured":"Asa SL, Mete O, Perry A, Osamura RY (2022) Overview of the 2022 WHO classification of Pituitary tumors. Endocr Pathol 33(1):6\u201326. https:\/\/doi.org\/10.1007\/s12022-022-09703-7","journal-title":"Endocr Pathol"},{"issue":"1","key":"1503_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11102-016-0768-4","volume":"20","author":"RM Paragliola","year":"2017","unstructured":"Paragliola RM, Corsello SM, Salvatori R (2017) Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance. Pituitary 20(1):109\u2013115. https:\/\/doi.org\/10.1007\/s11102-016-0768-4","journal-title":"Pituitary"},{"issue":"2","key":"1503_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s12020-023-03317-7","volume":"80","author":"A Giustina","year":"2023","unstructured":"Giustina A, di Filippo L, Uygur MM, Frara S (2023) Modern approach to resistant acromegaly. Endocrine 80(2):303\u2013307. https:\/\/doi.org\/10.1007\/s12020-023-03317-7","journal-title":"Endocrine"},{"issue":"2","key":"1503_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00701-020-04609-x","volume":"163","author":"L Galloway","year":"2021","unstructured":"Galloway L, Ali M, Lansdown A et al (2021) The impact of endoscopic transsphenoidal pituitary adenoma surgery on endocrine function: a single-centre study. Acta Neurochir 163(2):391\u2013398. https:\/\/doi.org\/10.1007\/s00701-020-04609-x","journal-title":"Acta Neurochir"},{"issue":"4","key":"1503_CR16","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/MED.0b013e3283631820","volume":"20","author":"KH Darzy","year":"2013","unstructured":"Darzy KH (2013) Radiation-induced hypopituitarism. Curr Opin Endocrinol Diabetes Obes 20(4):342\u2013353. https:\/\/doi.org\/10.1097\/MED.0b013e3283631820","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"1503_CR17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s11060-018-2792-x","volume":"138","author":"MR Patibandla","year":"2018","unstructured":"Patibandla MR, Xu Z, Sheehan JP (2018) Factors affecting early versus late remission in acromegaly following stereotactic radiosurgery. J Neurooncol 138(1):209\u2013216. https:\/\/doi.org\/10.1007\/s11060-018-2792-x","journal-title":"J Neurooncol"},{"key":"1503_CR18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.wneu.2016.10.029","volume":"97","author":"K Phan","year":"2017","unstructured":"Phan K, Xu J, Reddy R, Kalakoti P, Nanda A, Fairhall J (2017) Endoscopic endonasal versus microsurgical transsphenoidal approach for growth hormone-secreting pituitary adenomas: systematic review and meta-analysis. World Neurosurg 97:398\u2013406. https:\/\/doi.org\/10.1016\/j.wneu.2016.10.029","journal-title":"World Neurosurg"},{"issue":"8","key":"1503_CR19","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1210\/jc.2013-1036","volume":"98","author":"RM Starke","year":"2013","unstructured":"Starke RM, Raper DM, Payne SC, Vance ML, Oldfield EH, Jane JA (2013) Jr. Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab 98(8):3190\u20133198. https:\/\/doi.org\/10.1210\/jc.2013-1036","journal-title":"J Clin Endocrinol Metab"},{"key":"1503_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.clineuro.2014.09.004","volume":"126","author":"S Sarkar","year":"2014","unstructured":"Sarkar S, Rajaratnam S, Chacko G, Chacko AG (2014) Endocrinological outcomes following endoscopic and microscopic transsphenoidal surgery in 113 patients with acromegaly. Clin Neurol Neurosurg 126:190\u2013195. https:\/\/doi.org\/10.1016\/j.clineuro.2014.09.004","journal-title":"Clin Neurol Neurosurg"},{"issue":"10","key":"1503_CR21","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1007\/s00701-023-05772-7","volume":"165","author":"CM Falch","year":"2023","unstructured":"Falch CM, Dupont AK, Olarescu NC et al (2023) Long-term control of acromegaly after pituitary surgery in South-Eastern Norway. Acta Neurochir (Wein) 165(10):3003\u20133010. https:\/\/doi.org\/10.1007\/s00701-023-05772-7","journal-title":"Acta Neurochir (Wein)"},{"issue":"8","key":"1503_CR22","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1210\/jcem.83.8.4995","volume":"83","author":"S Melmed","year":"1998","unstructured":"Melmed S, Jackson I, Kleinberg D, Klibanski A (1998) Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 83(8):2646\u20132652. https:\/\/doi.org\/10.1210\/jcem.83.8.4995","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1503_CR23","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1210\/jc.2009-2670","volume":"95","author":"A Giustina","year":"2010","unstructured":"Giustina A, Chanson P, Bronstein MD et al (2010) Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95(7):3141\u20133148. https:\/\/doi.org\/10.1210\/jc.2009-2670","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1503_CR24","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P et al (2018) A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14(9):552\u2013561. https:\/\/doi.org\/10.1038\/s41574-018-0058-5","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"1503_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Biermasz N, Casanueva FF et al (2024) Consensus on criteria for acromegaly diagnosis and remission. Pituitary 27(1):7\u201322. https:\/\/doi.org\/10.1007\/s11102-023-01360-1","journal-title":"Pituitary"},{"issue":"1","key":"1503_CR26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s11102-023-01373-w","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Biermasz N, Casanueva FF et al (2024) Correction: consensus on criteria for acromegaly diagnosis and remission. Pituitary 27(1):88. https:\/\/doi.org\/10.1007\/s11102-023-01373-w","journal-title":"Pituitary"},{"issue":"1","key":"1503_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/eje.1.02186","volume":"155","author":"PJ Trainer","year":"2006","unstructured":"Trainer PJ, Barth J, Sturgeon C, Wieringaon G (2006) Consensus statement on the standardisation of GH assays. Eur J Endocrinol 155(1):1\u20132. https:\/\/doi.org\/10.1530\/eje.1.02186","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1503_CR28","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3171\/2014.12.JNS141083","volume":"122","author":"AS Micko","year":"2015","unstructured":"Micko AS, W\u00f6hrer A, Wolfsberger S, Knosp E (2015) Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg 122(4):803\u2013811. https:\/\/doi.org\/10.3171\/2014.12.JNS141083","journal-title":"J Neurosurg"},{"issue":"1","key":"1503_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/02841859709171238","volume":"38","author":"AL Edal","year":"1997","unstructured":"Edal AL, Skj\u00f6dt K, Nepper-Rasmussen HJ (1997) SIPAP: a new MR classification for pituitary adenomas. Suprasellar, infrasellar, parasellar, anterior and posterior. Acta Radiol 38(1):30\u201336. https:\/\/doi.org\/10.1080\/02841859709171238","journal-title":"Acta Radiol"},{"issue":"2","key":"1503_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1365-2265.2012.04492.x","volume":"78","author":"F Albarel","year":"2013","unstructured":"Albarel F, Castinetti F, Morange I et al (2013) Outcome of multimodal therapy in operated acromegalic patients, a study in 115 patients. Clin Endocrinol (Oxf) 78(2):263\u2013270. https:\/\/doi.org\/10.1111\/j.1365-2265.2012.04492.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"1503_CR31","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s10143-020-01340-0","volume":"44","author":"EL Sorba","year":"2021","unstructured":"Sorba EL, Staartjes VE, Voglis S et al (2021) Diabetes insipidus and syndrome of inappropriate antidiuresis (SIADH) after pituitary surgery: incidence and risk factors. Neurosurg Rev 44(3):1503\u20131511. https:\/\/doi.org\/10.1007\/s10143-020-01340-0","journal-title":"Neurosurg Rev"},{"issue":"6","key":"1503_CR32","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s11102-021-01159-y","volume":"24","author":"M Castle-Kirszbaum","year":"2021","unstructured":"Castle-Kirszbaum M, Fuller P, Wang YY, King J, Goldschlager T (2021) Diabetes insipidus after endoscopic transsphenoidal surgery: multicenter experience and development of the SALT score. Pituitary 24(6):867\u2013877. https:\/\/doi.org\/10.1007\/s11102-021-01159-y","journal-title":"Pituitary"},{"issue":"2","key":"1503_CR33","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s13760-012-0151-9","volume":"113","author":"A Dusart","year":"2013","unstructured":"Dusart A, Duprez T, van Snick S, Godfraind C, Sindic C (2013) Fatal rhinocerebral mucormycosis with intracavernous carotid aneurysm and thrombosis: a late complication of transsphenoidal surgery? Acta Neurol Belg 113(2):179\u2013184. https:\/\/doi.org\/10.1007\/s13760-012-0151-9","journal-title":"Acta Neurol Belg"},{"issue":"5","key":"1503_CR34","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1365-2265.1991.tb03559.x","volume":"35","author":"TM Fiad","year":"1991","unstructured":"Fiad TM, McKenna TJ (1991) Meningitis as a late complication of surgically and medically treated pituitary adenoma. Clin Endocrinol (Oxf) 35(5):419\u2013422. https:\/\/doi.org\/10.1111\/j.1365-2265.1991.tb03559.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"1503_CR35","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11154-022-09710-3","volume":"23","author":"M Bolanowski","year":"2022","unstructured":"Bolanowski M, Ka\u0142u\u017cny M, Witek P, Jawiarczyk-Przyby\u0142owska A (2022) Pasireotide: a novel somatostatin receptor ligand after 20 years of use. Rev Endocr Metab Disord 23(3):601\u2013620. https:\/\/doi.org\/10.1007\/s11154-022-09710-3","journal-title":"Rev Endocr Metab Disord"},{"issue":"Suppl 2","key":"1503_CR36","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1530\/eje.0.148s027","volume":"148","author":"PM Stewart","year":"2003","unstructured":"Stewart PM (2003) Pegvisomant: an advance in clinical efficacy in acromegaly. Eur J Endocrinol 148(Suppl 2):S27\u201332. https:\/\/doi.org\/10.1530\/eje.0.148s027","journal-title":"Eur J Endocrinol"},{"issue":"9295","key":"1503_CR37","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/s0140-6736(01)06844-1","volume":"358","author":"AJ van der Lely","year":"2001","unstructured":"van der Lely AJ, Hutson RK, Trainer PJ et al (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358(9295):1754\u20131759. https:\/\/doi.org\/10.1016\/s0140-6736(01)06844-1","journal-title":"Lancet"},{"issue":"1","key":"1503_CR38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11102-012-0384-x","volume":"16","author":"G Sesmilo","year":"2013","unstructured":"Sesmilo G, Gaztambide S, Venegas E et al (2013) Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA). Pituitary 16(1):115\u2013121. https:\/\/doi.org\/10.1007\/s11102-012-0384-x","journal-title":"Pituitary"},{"issue":"4","key":"1503_CR39","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/MED.0b013e328204c472","volume":"14","author":"M Mayberg","year":"2007","unstructured":"Mayberg M, Vermeulen S (2007) Advances in stereotactic radiosurgery in the treatment of pituitary adenomas. Curr Opin Endocrinol Diabetes Obes 14(4):296\u2013300. https:\/\/doi.org\/10.1097\/MED.0b013e328204c472","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"1503_CR40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1530\/EJE-18-0255","volume":"179","author":"F Bolfi","year":"2018","unstructured":"Bolfi F, Neves AF, Boguszewski CL, Nunes-Nogueira VS (2018) Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol 179(1):59\u201371. https:\/\/doi.org\/10.1530\/EJE-18-0255","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1503_CR41","doi-asserted-by":"publisher","first-page":"L5","DOI":"10.1530\/EJE-19-0509","volume":"181","author":"F Bolfi","year":"2019","unstructured":"Bolfi F, Neves AF, Boguszewski CL, Nunes-Nogueira VS (2019) Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol 181(5):L5\u20136. https:\/\/doi.org\/10.1530\/EJE-19-0509","journal-title":"Eur J Endocrinol"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01503-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-025-01503-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01503-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T04:46:24Z","timestamp":1746506784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-025-01503-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1503"],"URL":"https:\/\/doi.org\/10.1007\/s11102-025-01503-6","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,22]]},"assertion":[{"value":"22 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Swedish Ethical Review Authority (Etikpr\u00f6vningsmyndigheten) (Dnr: 2019\u201304779).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"A.P., T.O.B., T.S., T.H., H.C., and G.J. has no conflict of interest to declare. D.E. has received lecture fees from Ipsen, Pfizer AB and Recordati Rare Disease. D.S.O. has been a consultant for Sandoz, Ipsen, and Pfizer; has received unrestricted grants from Sandoz and Pfizer; and is an employee at AstraZeneca as of 8 August 2021.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}